This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Freeman, D. Articles by Wu, H. Search for Related Content PubMed PubMed Citation Articles by Freeman, D. Articles by Wu, H.

Genetic Background Controls Tumor Development in Pten-Deficient Mice

Departments of ¹ Molecular and Medical Pharmacology and ² Pathology and Laboratory Medicine, University of California at Los Angeles School of Medicine, Los Angeles, California

Requests for reprints: Hong Wu, Department of Molecular and Medical Pharmacology, University of California at Los Angeles School of Medicine, 650 CE Young Drive South, Los Angeles, CA 90095-1735. Phone: 310-825-5160; Fax: 310-267-0242; E-mail: hwu{at}mednet.ucla.edu.

PTEN is one of the most frequently mutated tumor suppressor genes in human cancers. Germ line mutations of PTEN have been detected in three rare autosomal-dominant disorders. However, identical mutations in the PTEN gene may lead to different symptoms that have traditionally been described as different disorders, such as Cowden disease, Lhermitte-Duclos disease, and Bannayan-Zonana syndromes. This lack of genotype-phenotype correlation prompted us to directly test the possible effects of genetic background or modifier genes on PTEN-controlled tumorigenesis using genetically engineered mouse models. In this study, we generated two animal models in which either exon 5 (Pten⁵) or promoter to exon 3 (Pten^–) of the murine Pten gene were deleted and compared phenotypes associated with individual mutations on two genetic backgrounds. We found that the onset and spectrum of tumor formation depend significantly on the genetic background but less on the type of mutation generated. Our results suggest that PTEN plays a critical role in cancer development, and genetic background may influence the onset, the spectrum, and the progression of tumorigenesis caused by Pten mutation. (Cancer Res 2006; 66(13): 6492-6)

This article has been cited by other articles:

				C. Tiozzo, S. De Langhe, M. Yu, V. A. Londhe, G. Carraro, M. Li, C. Li, Y. Xing, S. Anderson, Z. Borok, et al. Deletion of Pten Expands Lung Epithelial Progenitor Pools and Confers Resistance to Airway Injury Am. J. Respir. Crit. Care Med., October 15, 2009; 180(8): 701 - 712. [Abstract] [Full Text] [PDF]

				J. Blando, M. Portis, F. Benavides, A. Alexander, G. Mills, B. Dave, C. J. Conti, J. Kim, and C. L. Walker PTEN Deficiency Is Fully Penetrant for Prostate Adenocarcinoma in C57BL/6 Mice via mTOR-Dependent Growth Am. J. Pathol., May 1, 2009; 174(5): 1869 - 1879. [Abstract] [Full Text] [PDF]

				O. Renner, C. Blanco-Aparicio, M. Grassow, M. Canamero, J. F.M. Leal, and A. Carnero Activation of Phosphatidylinositol 3-Kinase by Membrane Localization of p110{alpha} Predisposes Mammary Glands to Neoplastic Transformation Cancer Res., December 1, 2008; 68(23): 9643 - 9653. [Abstract] [Full Text] [PDF]

				C. K. Ratnacaram, M. Teletin, M. Jiang, X. Meng, P. Chambon, and D. Metzger Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma PNAS, February 19, 2008; 105(7): 2521 - 2526. [Abstract] [Full Text] [PDF]

				T. Tamguney and D. Stokoe New insights into PTEN J. Cell Sci., December 1, 2007; 120(23): 4071 - 4079. [Abstract] [Full Text] [PDF]

				J. Shao, M.K. Washington, R. Saxena, and H. Sheng Heterozygous disruption of the PTEN promotes intestinal neoplasia in APCmin/+ mouse: roles of osteopontin Carcinogenesis, December 1, 2007; 28(12): 2476 - 2483. [Abstract] [Full Text] [PDF]

				K L Lachlan, A M Lucassen, D Bunyan, and I K Temple Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers J. Med. Genet., September 1, 2007; 44(9): 579 - 585. [Abstract] [Full Text] [PDF]

				J. Jiao, S. Wang, R. Qiao, I. Vivanco, P. A. Watson, C. L. Sawyers, and H. Wu Murine Cell Lines Derived from Pten Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development Cancer Res., July 1, 2007; 67(13): 6083 - 6091. [Abstract] [Full Text] [PDF]

				C. Blanco-Aparicio, O. Renner, J. F.M. Leal, and A. Carnero PTEN, more than the AKT pathway Carcinogenesis, July 1, 2007; 28(7): 1379 - 1386. [Abstract] [Full Text] [PDF]